Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 12, 2004, Pages 809-829

  Ohmori, Kenji ^a   Hasegawa, Kazuhide ^a   Tamura, Tadafumi ^a   Miyake, Kiyomi ^a   Matsubara, Masahiro ^a   Masaki, Shigehiro ^a   Karasawa, Akira ^a   Urayama, Naoko ^a   Horikoshi, Kaori ^a   Kajita, Jiro ^a   Hasegawa, Masanori ^a   Taniguchi, Koji ^a   Komada, Toshio ^a   Kawamoto, Yuji ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Allergic rhinoconjunctivitis; Antiallergic agent; CAS 140462 76 6; Chronic urticaria; Cutaneous diseases with pruritus; Olopatadine hydrochloride, review of the properties

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; ALPHA4 INTEGRIN; CALCITONIN GENE RELATED PEPTIDE; CD11B ANTIGEN; CD18 ANTIGEN; CHLORPHENIRAMINE; G PROTEIN COUPLED RECEPTOR; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H3 RECEPTOR; IMMUNOGLOBULIN E; INTERLEUKIN 5; INTERLEUKIN 6; LANEPITANT; LEUKOTRIENE; LEUKOTRIENE D4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHYSERGIDE; NEUROKININ A; OLOPATADINE; PHOSPHOLIPASE A2; PHOSPHORAMIDON; PRANLUKAST; SAREDUTANT; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ALLERGIC RHINITIS; ALLERGY; CYTOKINE RELEASE; DRUG ABSORPTION; DRUG APPROVAL; DRUG ELIMINATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; ECZEMA; ERYTHEMA MULTIFORME; IC 50; IMMUNOMODULATION; IMMUNOPATHOGENESIS; NONHUMAN; PRURIGO; PSORIASIS VULGARIS; REVIEW; RHINOCONJUNCTIVITIS; SYSTEMATIC REVIEW;

EID: 10644237902     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297036     Document Type: Review

References (135)

1. Ohshima, E., Otaki, S., Sato, H. et al., Synthesis and antiallergic activities of 11-(aminoalklidene)-6,11-dyhydrodibenz [b,e]oxepin derivatives. J. Med. Chem. 35, 2074 (1992)
2. Ohmori, K., Hayashi, K., Kaise, T. et al., Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn. J. Pharmacol. 88, 379 (2002)
3. Nakano, K., Takamatsu, S. Histamine produced by macrophage and T lymphocyte: a new type of signal transducer. Folia Pharmacol. Jpn. 118, 15 (2001) (text in Japanese with English abstract)
4. Shiraishi, M., Hirakawa, N., Oikawa, S. et al., Analysis of histamine-producing cells at the late phase of allergic inflammation in rats. Immunology 99, 600 (2000)
5. 1 receptors. Clin. Pharmacol. Ther. 5, 1817 (1995)
6. Sharif, N. A., Xu, S. X., Miller, S. T. et al., Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J. Pharmacol. Exp. Ther. 278, 1252 (1996)
7. 1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J. Ocular Pharmacol. 12, 401 (1996)
8. 194. Biochem. Biophys. Res. Commun. 203, 1096 (1994)
9. 1 receptor. Eur. J. Pharmacol. 345, 111 (1998)
10. Sasaki, Y., Ishii, H., Ikemura, T. et al., The antihistaminic effect of KW-4679, a novel antiallergic drug. Clin. Pharmacol. Ther. 5, 1817 (1995) (text in Japanese with English abstract)
11. Ley, K., Tedder, T. F., Leukocyte interactions with vascular endothelium. New insights into selectin-mediated attachment and rolling. J. Immunol. 155, 525 (1995)
12. Miki, I., Kusano, A., Ohta, S. et al., Histamine enhanced the TNF-a-induced expression of E-selectin and ICAM-1 on vascular endothelial cells. Cell Immunol. 171, 285 (1996)
13. Takizawa, H., Ohtoshi, T., Kikutani, T. et al., Histamine activates bronchial epithelial cells to release inflammatory cytokines in vitro. Int. Arch. Allergy Immunol. 108, 260 (1995)
14. Yanni, J. M., Weimer, L. K., Sharif, N. A. et al., Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch. Ophtalmol. 117, 643 (1999)
15. Caron, G., Delneste, Y., Roelandts, E. et al., Histamine induces CD86 expression and chemokine production by human immature dendritic cells. J. Immunol. 166, 6000 (2001)
16. Ohtani, T., Aiba, S., Mizuashi, M. et al., Evaluation of the efficacy of antihistamines using human monocyte-derived dendritic cells stimulated with histamine. J. Am. Acad. Dermatol. 49, 234 (2003)
17. Sirois, M. G., Plante, G. E., Braquet, P. Role of eicosanoids in PAF-induced increases of the vascular permeability in rat airway. Br. J. Pharmacol. 101, 896 (1990)
18. Samuelsson, B., Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220, 568 (1983)
19. Sasaki, Y., Ikeda, Y., Ikemura, T. et al., Effect of KW-4679, an novel antiallergic drug, on histamine and leukotriene release from rat peritoneal exudates cells. Clin. Pharmacol. Ther. 5, 1837 (1995) (text in Japanese with English abstract)
20. Yanni, J. M., Miller, S. T., Gamache, D. A. et al., Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann. Allergy Asthma Immunol. 79, 541 (1997)
21. Ikemura, T., Manabe, H., Sasaki, Y. et al., KW-4679, an antiallergic drug, inhibits the production of inflammatory lipids in human polymorphonuclear leukocyte and guinea pig eosinophils. Int. Arch. Allergy Immunol. 110, 57 (1996)
22. Miyake, K., Ohmori, K., Ishii, A. et al., Inhibitory effects of olopatadine hydrochloride (KW-4679), a novel antiallergic drug, on peptide leukotrienes release from human eosinophils. Allergol. Int. 50, 113 (2001)
23. Miyake, K., Horikoshi, K., Ikeda, Y. et al., Effect of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs. Jpn. J. Pharmacol. 85, 453 (2001)
24. Kaise, T., Akamatsu, Y., Ohmori, K. et al., Effect of olopatadine hydrochloride on the thromboxane B2 and histamine from nasal mucosa after antigen-antibody reaction in guinea pigs. Allergol. Int. 50, 337 (2001)
25. Numata, T., Konno, A., Yamakoshi, T. et al., Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann. Otol. Rhinol. Laryngol. 108, 467 (1999)
26. 2 receptor antagonist, on nasal cavity volume and minimum cross-sectioned area and nasal mucosal hemodynamics after nasal mucosal allergen challenge in patients with perennial allergic rhinitis. Acta. Otolaryngol. Suppl. 537, 32 (1998)
27. Matsubara, M., Masaki, S., Ohmori, K. et al., Differential regulation of IL-4 expression and degranulation by anti-allergic olopatadine in rat basophillic leukemia (RBL-2H3) cells. Biochem. Pharmacol. 67, 1315 (2004)
28. Shiahibori, T., Oyama, Y., Matsushita, O. et al., Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family. Biochem. J. 338, 583 (1999)
29. Okada, M., Tokumitsu, H., Kubota, Y. et al., Interaction of S100 protein with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem. Biophys. Res. Commun 292, 1023 (2002)
30. Lundberg, L. M., Lundberg, L., Martling, C. R. et al., Coexistence of multiple peptide and classical transmitters in airway neurons: functional and pathophysiologic aspect. Am. Rev. Respir. Dis. 136, S16 (1987)
31. Barnes, P. J., New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. J. Allergy Clin. Immunol. 83, 1013 (1989)
32. Laitinen, L. A., Heijo, M., Laitinen, A. et al., Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am. Rev. Respir. Dis. 131, 599 (1985)
33. Baraniuk, J. N., Lundgren, J. D., Okayama, M. et al., Substance P and neurokinin A in human nasal mucosa. Am. J. Respir. Cell Mol. Biol. 4, 228 (1991)
34. Uddman, R., Cantera, L., Cardella, L. O., Expression of NPY Y1 and CGRP receptors in human nasal mucosa: implications in allergic rhinitis. Ann. Otol. Rhinol. Laryngol. 108, 969 (1999)
35. Braumstein, G., Fajak, I., Lacronique, J. et al., Clinical and inflammatory responses to exogeneous tachykinins in allergic rhinitis. Am. Rev. Respir. Dis. 144, 630 (1991)
36. Ranji, S. P., Sample, S., Serwonska, M. H. et al., Mediation of prolonged increases in nasal mucosal blood flow by calcitonin gene-related peptide (CGRP). J. Clin. Immunol. 10, 304 (1990)
37. Konno, A., Numata, T., Terada, N., Role of substance P in the vascular responses of nasal mucosa in nasal allergy. Ann. Otol. Rhinol. Laryngol. 105, 648 (1996)
38. Weidner, C., Klede, M., Rukwied, R. et al., Acute effects of substance P and calcitonin gene-related peptide in human skin - a microdialysis study. J. Invest. Dermatol. 115, 1015 (2000)
39. Holzer, P., Neurogenic vasodilation and plasma leakage in the skin. Gen. Pharmacol. 30, 5 (1998)
40. Scholzen, T., Armstrong, C. A., Bunnett, L. W. et al., Neuropeptide in the skin: interactions between the neurocrine and the skin immune systems. Exp. Dermatol. 7, 81 (1998)
41. Grundstrom, N., Andersson, R. G. G., Wikberg, J. E. S., Pharmacological characterization of the guinea pig tracheobronchial smooth muscle. Acta. Pharmacol. Toxicol. 49, 150 (1981)
42. Ikemura, T., Okamura, K., Sasaki, Y. et al., KW-4679-induced inhibition of tachykininergic contraction in the guinea pig brochi by prejunctional inhibition of peripheral sensory nerve. Br. J. Pharmacol. 117, 967 (1996)
43. 2) receptor. Life Sci. 50, PL101 (1992)
44. Ikemura, T., Sasaki, Y., Ishii, H. and Ohmori, K., Inhibitory effect of KW-4679, an anti-allergic drug, on tachykinin-mediated airway response induced by electrical stimulation in guinea pigs. Jpn. J. Pharmacol. 71, 179 (1996)
45. Kaise, T., Akamatsu, Y., Ikemura, T. et al., Involvement of neuropeptides in the allergic nasal obstruction in guinea pigs. Jpn. J. Pharmacol. 86, 196 (2001)
46. Gitter, B. D., Bruns, R. F., Howbert, J. J. et al., Pharmacological characterization of LY303870: a novel, potent and selective substance P (neurokinin-1) receptor antagonist. J. Pharmacol. Exp. Ther. 275, 737 (1995)
47. Mimeault, M., Fournier, A., Dumont, Y. et al., Comparative affinities and antagonistic potencies of various human calcitonin gene-related peptide receptors in brain and periphery. J. Pharmacol. Exp. Ther. 258, 1084 (1991)
48. Kaise, T., Ohmori, K., Sakakura, Y. and Ukai, K. The effect of KW-4679, an antiallergic drug, on experimental allergic rhinitis in guinea pigs: effects on nasal blockage. Jpn. J. Pharmacol. 69, 435 (1995)
49. Kaise, T., Akamatsu, Y., Ohmori, K. et al., Inhibitory effect of olopatadine hydrochloride on the sneezing response induced by intranasal capsaicin challenge in guinea pigs. Jpn. J. Pharmacol. 86, 258 (2001)
50. Lundblad, L., Lundberg, J. M., Anggard, A. Local and systemic capsaicin pretreatment inhibits sneezing and increase in nasal permeability induced by certain chemical irritants. Naunyn. Scmiedebergs Arch. Pharmacol. 326, 254 (1984)
51. Imamura, T., Kambara, T., Substance P as a potent stimulator of sneeze responses in experimental allergic rhinitis of guinea pigs. Agents Actions 37, 24 (1992)
52. Kitajiri, M., Kubo, N., Ikeda, H. et al., Effects of topical capsaicin on autonomic nerves in experimentally-induced nasal hypersensitivity. An immunocytochemical study. Acta. Otolaryngol. Suppl. 500, 88 (1993)
53. Mcevoy, M. T., Peterson, E. A., Kobza-Black, A. et al., Immunohistological comparison of granulated cell proteins in immediate urticaria dermographism and delayed pressure urticaria lesions. Br. J. Dermatol. 133, 853 (1995)
54. Wasmoen, T. L., Bell, M. P., Loegering, D. A. et al., Biochemical and amino acid sequence analysis of human eosinophil granule major basic protein. J. Biol. Chem. 263, 1255 (1988)
55. Leiferman, K. M., Loegering, D. A., Gleich, G. J., Production of wheal-and-flare skin reactions by eosinophil granule proteins. J. Invest. Dermatol. 82, 414 (1984)
56. Peters, M. S., Schroeter, A. L., Kephart, G. M. et al., Localization of eosinophil granule major basic protein in chronic urticaria. J. Invest. Dermatol. 81, 39 (1983)
57. Coyle, A. J., Ackerman, S. J., Irvin, C. G., Cationic proteins induce airway hyperresponsiveness dependent on charge interactions. Am. Rev. Respir. Dis. 147, 896 (1993)
58. Uchida, D. A., Ackerman, S. J., Coyle, A. J. et al., The effect of human eosinophil granule major basic protein on airway responsiveness in the rat in vivo. Am. Rev. Respir. Dis. 147, 982 (1993)
59. Stein, O., De Vries, A., Katachalski, E., The effect of polyamino acid on the blood vessels of the rat. Arch. Int. Pharmacodyn. 57, 243 (1956)
60. Foreman, J. C., Jordan, C. C., Oehme, P. et al., Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin. J. Physiol. (Lond) 335, 449 (1983)
61. Benyon, R. C., Robinson, C., Church, M. K., Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. Br. J. Pharmacol. 97, 898 (1989)
62. Garland, A., Necheles, J., White, S. R. et al., Activated eosinophils elicit substance P release from cultured dorsal root ganglion neurons. Am. J. Physiol. 273, L1096 (1997)
63. Hayashi, K., Sato, H., Kaise, T. et al., Roles of mast cells and sensory nerves in cutaneous vascular hyperpermeability and scratching behavior induced by poly-L-arginine in rats. Eur. J. Pharmacol. 425, 219 (2001)
64. Hayashi, K., Kaise, T., Ohmori, K., Effects of olopatadine hydrochloride on the cutaneous vascular hyperpermeability and scratching behavior induced by poly-L-arginine in rats. Jpn. J. Pharmacol. 87, 167 (2001)
65. Tokura, S., Kobayashi, M., Ito, Y. et al., Anti-allergic drug olopatadine suppresses murine contact hypersensitivity and downregulates antigen-presenting ability of epidermal Langerhans cells. Cellular Immunol 224, 47 (2003)
66. Miyake, K., Kaise, T., Urayama, N. et al., Amelioration by olopatadine hydrochloride (Allelock), an antiallergic drug, on nasal blockage of allergic rhinitis: comparison with the pre-exiting antiallergic drugs and the mechanism of action. Allergy in Practice 300, 63 (2003) (text in Japanese)
67. Kaise, T., Ukai, K., Pedersen, O. F. et al., Accuracy of measurement of acoustic rhinometry applied to small experimental animals. Am. J. Rhinology 13, 125 (1999)
68. Terada, N., Konno, A., Togawa, K., Biochemical properties of eosinophils and their preferential accumulation mechanism in nasal allergy. J. Allergy Clin. Immunol. 94, 629 (1994)
69. Akagi, M., Fukuishi, N., Shimono, T. et al., Inhibitory effect of KW-4679 on the infiltration of eosinophils in the nasal mucosa of rat allergic rhinitis models. Jpn. Pharmacol. Ther. 29, 187 (2001) (text in Japanese with English abstract)
70. Fukuishi, N.., Matsushita, M., Shimono, T. et al., Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 in eosinophils. Jpn. J. Pharmacol. 88, 463 (2002)
71. Kamei, C., Sugimoto, Y., Nakamara, S. et al., Effect of 11- [(Z)- 3- (dimetylamino) propylidene]- 6,11- dihydrodibenz [b,e]oxepin-2-acetic acid monohydrochloride on experimental allergic conjunctivitis and rhinitis in rats and in guinea pigs. Arzneim.-Forsch./Drug Res. 45 (II), 1005 (1995)
72. Tamura, T., Sato, H., Ohmori, K. et al., Effects of orally administered olopatadine hydrochloride on the ocular allergic reaction in rats. Allergol. Int. 52, 77 (2003)
73. 1 receptor deficient mice. Jpn. J. Allergol. 52, 944 (2003) (text in Japanese)
74. 1 receptor-deficient and mast cell-deficient mice. J. Pharmacol. Sci. 94, 203P (2004)
75. st report) - effects on central nervous system, autonomic nervous system and peripheral nervous system. Clin. Pharmacol. Ther. 5, 1421 (1995) (text in Japanese with English abstract)
76. nd report)- effects on respiratory and circulatory system, urogenital system and digestive system. Clin. Pharmacol. Ther. 5, 2155 (1995) (text in Japanese with English abstract)
77. Saeki, K., Sadanaga, O., Ikegami, T. et al., A single dose toxicity study of KW-4679 in mice, rats and dogs. Clin. Report 29, 4727 (1995) (text in Japanese with English abstract)
78. Ikegami, J., Sano, J., Sadanaga, O. et al., Toxicity studies of KW-4679 - a 13 week repeated dose toxicity study in rats. Clin. Report 29, 4749 (1995) (text in Japanese with English abstract)
79. Ikegami, J., Furumoto, H., Sano, J., et al. Toxicity studies of KW-4679 - a 52 week repeated dose toxicity study in dogs. Clin. Report 29, 4787 (1995) (text in Japanese with English abstract)
80. Naya, M., Kito, Y., Deguchi, T. Reproductive and developmental toxicity study of KW-4679 - fertility study in rats. Clin. Report 29, 4803 (1995) (text in Japanese with English abstract)
81. Naya, M., Sakuma, T., Matsusige, M. et al., Reproductive and developmental toxicity study of KW-4679 - teratogenicity study in rats. Clin. Report 29, 4815 (1995) (text in Japanese with English abstract)
82. Naya, M., Kojima, N., Imoto, H. et al., Reproductive and developmental toxicity study of KW-4679 - teratogenicity study in rabbits. Clin. Report 29, 4841 (1995) (text in Japanese with English abstract)
83. Yanai, K., Tashiro, M., Motizuki, H. et al., CNS effects of antihistamines. Allergy Pract. 297, 87 (2002) (text in Japanese)
84. Asano, K., Ohtubo, S., New approach to avoid the unfavorable sedative effects of histamine H1 receptor antagonists. Medico 35, 205 (2004) (text in Japanese)
85. Tamargo, J., Drug-induced torsades de pointes: from molecular biology to bedside. Jpn. J. Pharmacol. 83, 1 (2000)
86. Kato, Y., Mori, T., Ohmori, K. et al., Effect of terfenadine and KW-4679, a novel antiallergic compound, on action potential of guinea pig ventricular myocytes. Jpn. J. Pharmacol. 70, 199 (1996)
87. Tanaka, H., Masumiya, H., Kato, Y. et al., Inhibitory effects of terfenadine on the rising phase of action potential and sinus rates in isolated guinea pig myocardium. Gen. Pharmacol. 27, 337 (1996)
88. Pohjola-Sintonen, S., Viitasalo, M., Toivonen, L. et al., Itraconazole prevents terfenadine metabolism and increase risk of torsades de pointes ventricular tachycardia. Eur. J. Clin. Pharmacol. 45, 191 (1993)
89. Iwamoto, K., Ikeda, J., Nito, M. et al., Effects of olopatadine hydrochloride, a novel antiallergic agent, on the QT interval. Folia Pharmacol. Jpn. 117, 401 (2001)
90. Brockman, H., Momsen, M., Knudtson, J. et al., Interaction of olopatadine and selected antihistamines with model and natural membranes. Ocul. Immunol. Inflamm. 11, 247 (2003)
91. Artal, M. N., Luna, J. D., Discepola, M., A forced choice comfort study of olopatadine hydrochloride 0.1 % versus ketotifen fumarate 0.05 %. Acta Optalmol. Scand. 78, 64 (2000)
92. Tsunoo, M., Nomomura, S., Masuo, M. et al., Phase 1 clinical study on KW-4679, an antiallergic drug - safety and pharmacokinetics in a single and repeated administration study in healthy subjects. Clin. Report 29, 4129 (1995) (text in Japanese with English abstract)
93. Fujita, K., Magara, H., Kobayashi, H., Determination of olopatadine, a new antiallergic agent, and its metabolites in human plasma by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. J. Chromatogr. 731, 345 (1999)
94. Tateishi, T., Kobayashi, S., Shigeyama, C. et al., Pharmacokinetics of KW-4679 in the elderly: single-dose and multiple-dose trials. Drugs Exp. Clin. Res. 29, 1 (1998)
95. Koshikawa, S., Akizawa, T., Kobayashi, S. et al., Pharmacokinetics of KW-4679 in patients with renal insufficiency. Kidney Dialysis 42, 107 (1997)
96. Kuwabara, T., Ohishi, T., Ikenaga, T. et al., Disposition of KW-4679 (6): pharmacokinetics in experimental animals. Xenobiot. Metab. Dispos. 10, 707 (1995) (text in Japanese with English abstract)
97. 14C-KW-4679 after oral or intravenous administration to rats. Xenobiot. Metab. Dispos. 10, 651 (1995) (text in Japanese with English abstract)
98. 14C-epinastine hydrochloride (WAL 801 Cl) (1). Blood level, tissue distribution and urinary excretion after single and repeated administration in rats. Jpn. Pharmacol. Ther. 20, 483 (1992) (text in Japanese with English abstract)
99. Sasaki, T., Takahashi, H., Hamada, T. et al., The biological fate of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperaxinyl) benzimidazole difumarate (KB-2413). II. distribution after single and multiple oral administration to rats. Xenobo. Metabol. Dispos. 2, 133 (1987) (text in Japanese with English abstract)
100. Ohishi, T., Magara, H., Yasuzawa, T. et al., Disposition of KW-4679 (4): metabolism of KW-4679 in rats and dogs. Xenobo. Metabol. Dispos. 10, 689 (1995) (text in Japanese with English abstract)
101. Kajita J., Inano K., Fuse E. et al., Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab. Dispos. 30, 1504 (2002)
102. Hamilton, S. A., Duddle, J., Herdman, M. J. et al., Comparison of a new antihistaminic and antiallergic compound KW4679 with terfenadine and placebo on skin and nasal provocation in atopic individuals. Clin. Exp. Allergy 24, 955 (1994)
103. Morita, K., Koga, T., Moroi, Y. et al., Rapid effects of olopatadine hydrochloride on the histamine-induced skin responses. J. Dermatol. 29, 709 (2002)
104. Furue, M., Terao, H., Koga, T. Effects of cetirizine and epinastine on the skin response to histamine iontophoresis. J. Dermatol. Sci 25, 59 (2001)
105. Ramboer, I., Bumbacea, R., Lazarescu, D. et al., Cetirizine and loratadine: a comparison using the ED50 in skin reactions. J. Int. Med. Res 28, 69 (2000)
106. Yamagiwa, M., Immediate effect of olopatadine hydrochloride (Allelock) on allergic nasal obstruction. J. New. Rem. Clin 51, 131 (2002) (text in Japanese with English abstract)
107. Baraniuk, J. N., Ali, M., Yuta, A. et al., Hypertonic saline nasal provocation stimulates nociceptive nerves, substance P release, and glandular mucous exocytosis in normal humans. Am. J. Respir. Crit. Care Med 160, 655 (1999)
108. Yuta, A., Majima, Y., Inhibitory effect of olopatadine hydrochloride on the release of substance P induced by hypertonic saline onto nasal mucosa. Jpn. J. Allergol 51, 999 (2002) (text in Japanese)
109. Gotoh, M., Ohkubo, K., A single-blind, placebo-controlled, crossover trial of olopatadine hydrochloride in patients with parennial allergic rhinitis: relationship with substance P in nasal epithelium and nasal discharge. Jpn. J. Allergol. 52, 341 (2003) (text in Japanese)
110. Leonardi, A., Abelson, M. B., Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin. Ther. 25, 2539 (2003)
111. Dogru, M., Ozmen, A., Erturk, H. et al., Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: an open-label study. Clin. Ther. 24, 1309 (2002)
112. Ohta, N., Kasajima, N., Aoyagi, M., The effect of Allelock on treatment of patients with seasonal grass pollinosis. Pract. Oto. Rhino. Laryngol. 95, 647 (2002) (text in Japanese with English abstract)
113. Yamashita, T., Terada, N., Hamano, N. et al., Involvement of vascular endothelial growth factor in nasal obstruction in patients with nasal allergy. Allergol. Int. 49, 183 (2000)
114. Kon, I., The effect of prophylactic treatment by olopatadine hydrochloride (Allelock) in patients with Japanese cedar pollinosis. Medical Consultation and New Remedies 38, 1192 (2001) (text in Japanese)
115. Shimada, H., Initial medication of olopatadine hydrochloride (Allelock) in patients with cedar pollen pollinosis. Prog. Med. 22, 2478 (2002) (text in Japanese)
116. Nishiyama, S., Okamoto, S., Ishibashi, Y. et al., Late phase 2 study of KW-4679 (olopatadine hydrochloride) on chronic urticaria - optimal dose finding study by double blind technique. J. Clin. Ther. Med. 17, 211 (2001) (text in Japanese with English abstract)
117. Nishiyama, S., Okamoto, S., Ishibashi, Y. et al., Phase 3 study of KW-4679 (olopatadine hydrochloride) on chronic urticaria - a double blind study in comparison with ketotifen fumarate. J. Clin. Ther. Med. 17, 237 (2001) (text in Japanese with English abstract)
118. Nishiyama, S., Okamoto, S., Ishibashi, Y. et al., Longterm treatment of KW-4679 (olopatadine hydrochloride) on chronic urticaria. J. Clin. Ther. Med. 17, 1597 (2001) (text in Japanese with English abstract)
119. Nakama, T., The effect of olopatadine hydrochloride (Allelock) on treatment of patients with chronic urticaria. Medical Consultation and New Remedies 39, 563 (2002) (text in Japanese)
120. Tokunaga, T., The clinical effects of olopatadine hydrochloride (Allelock) in patients with chronic urticaria. Medical Consultation and New Remedies 39, 651 (2002) (text in Japanese)
121. Tanaka, M., Yamamoto, N., Clinical effects of olopatadine hydrochloride on acute and chronic urticaria - comparison trail with other antihistamines- Medical Consultation and New Remedies 40, 99 (2003) (text in Japanese)
122. Morita, E., Matsuo, H., Dekio, S., The treatment with Allelock (Olopatadine hydrochloride) for patients with factitious urticaria. Nishinihon J. Dermatol. 65, 172 (2003) (text in Japanese with English abstract)
123. Nishiyama, S., Okamoto, S., Ishibashi, Y. et al., Clinical study of KW-4679 (olopatadine hydrochloride) on pruritic diseases. J. Clin. Ther. Med. 12, 1615 (2001) (text in Japanese with English abstract)
124. Yamada, H., Clinical effects of olopatadine on pruritus with atopic dermatitis. Med. Trib. 35, 27 (2002) (text in Japanese)
125. Fukiage, T., Clinical efficacy of olopatadine hydrochloride (Allelock) on eczematous external auditory canal with itching. Medical Consultation and New Remedies 39, 171 (2002) (text in Japanese)
126. Friedlaender, M. H., The current and future therapy of allergic conjunctivitis. Curr. Opin. Ophthalmol. 9, 54 (1998)
127. Abelson, M. B., Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using conjunctival allergen challenge. Ann. Allergy Asthma Immunol. 81, 211 (1998)
128. Spangler, D. L., Bensch, G., Berdy, G. J., Evaluation of the efficacy of olopatadine hydrochloride 0.1 % ophthalmic solution and azelastine hydrochloride 0.05 % ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther. 23, 1272 (2001)
129. Burtrus, S., Greiner, J. V., Discepola, M., Finegold, I., Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1 % ophthalmic solution and nedcromil sodium 2 % ophthalmic solution in the human conjunctival allergen challenge model. Clin. Ther. 22, 1462 (2000)
130. Katelaris, C. H., Ciprandi, G., Missotten, L. et al., A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1 % ophthalmic solution and cromolyn sodium 2 % ophthalmic solution in seasonal allergic conjunctivitis. Clin. Ther. 24, 1561 (2002)
131. Besehenes, J., Discepola, M., Abelson, M., Comparative evaluation of olopatadine ophthalmic solution (0.1 %) versus ketorolac ophthalmic solution (0.5 %) using provocative antigen challenge model. Acta Ophthalmol. Scand. 77, 47 (1999)
132. Lanier, B. Q., Gross, R. D., Marks, B. B. et al., Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Ann. Allergy Asthma Immunol. 86, 641 (2001)
133. Abelson, M. B., Lanier, R. O., The added benefit of local patanol therapy when combined with systemic claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. Acta Ophthalmol. Scand. 77, 53 (1999)
134. Lanier, B. D., Abelson, M. B., Berger, W. E. et al. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clin. Ther. 24, 1161 (2002)
135. Slagle, W. S., Slagle, A. M., Brough, G. H., Mucus fishing syndrome: case report and new treatment option. Optometry 72, 634 (2001)